Background: The effect of treatment with either 200 mg·kg–1 of L-carnitine (LC) or propionyl-L-carnitine (PLC) was studied on endothelial dysfunction of small mesenteric arteries (SMA) from spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats. Methods: Systolic blood pressure (SBP) was measured and endothelial and vascular functions were assessed by the effect of carbachol (CCh) and phenylephrine (Phe). O2– produced by SMA and eNOS expression were evaluated by chemiluminescence and Western blot, respectively. Results: Although SBP was not affected, endothelial relaxation increased in both LC- and PLC-treated SHR. Nevertheless, the CCh-induced contraction remained sensitive to indomethacin in these rats. On the contrary, NO participation was increased in all the groups except for LC-treated WKY. Furthermore, high concentrations of Phe produced NO-dependent relaxation of SMA from PLC-treated rats. Both compounds decreased basal and NADPH-stimulated O2– in SHR toward values observed in WKY. Only PLC increased eNOS protein expression in SHR. Neither LC nor PLC affected endothelium-derived hyperpolarizing factor-induced relaxation. Conclusions: LC and its propionate improved endothelial responses of SMA from SHR by decreasing O2– production and thus increasing NO availability. PLC also increased NO synthesis by enhancing eNOS expression.

Keywords:
L-Carnitine, Endothelium, Hypertension, Nitric oxide, Nitric oxide synthase, Propionyl-L-carnitine, SHR, Small mesenteric arteries, Superoxide anion
1.
Herrera MD, Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, Vazquez CM, Marhuenda E: Endothelium-dependent vasorelaxation induced by L-carnitine in isolated aorta from normotensive and hypertensive rats. J Pharm Pharmacol 2002;54:1423–1427.
2.
Cipolla MJ, Nicoloff A, Rebello T, Amato A, Portes JM: Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg 1999;29:1097–1103.
3.
Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, Gomez-Amores L, Vazquez CM, Herrera MD: L-Carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci 2005;77:2082–2097.
4.
Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH: EDHF: bringing the concepts together. Trends Pharmacol Sci 2002;23:374–380.
5.
Mombouli JV, Vanhoutte PM: Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999;31:61–74.
6.
Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA: Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999;33:1353–1358.
7.
Fujii K, Tominaga M, Ohmori S, Kobayashi K, Koga T, Takata Y, Fujishima M: Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneously hypertensive rats. Circ Res 1992;70:660–669.
8.
Onaka U, Fujii K, Abe I, Fujishima M: Antihypertensive treatment improves endothelium-dependent hyperpolarization in the mesenteric artery of spontaneously hypertensive rats. Circulation 1998;98:175–182.
9.
Goto K, Fujii K, Onaka U, Abe I, Fujishima M: Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000;36:575–580.
10.
Rauchová H, Dobesová Z, Drahota Z, Zicha J, Kunes J: The effect of chronic L-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats. Eur J Pharmacol 1998;342:235–239.
11.
Berrougui H, Alvarez de Sotomayor M, Perez-Guerrero C, Ettaib A, Hmamouchi M, Marhuenda E, Herrera MD: Argan (Argania spinosa) oil lowers blood pressure and improves endothelial dysfunction in spontaneously hypertensive rats. Br J Nutr 2004;92:921–929.
12.
Briones AM, Alonso MJ, Hernanz R, Tovar S, Vila E, Salaices M: Hypertension alters the participation of contractile prostanoids and superoxide anions in lipopolysaccharide effects on small mesenteric arteries. Life Sci 2002;71:1997–2014.
13.
Münzel T, Afanas’ev IB, Kleschyov AL, Harrison DG: Detection of superoxide in vascular tissue. Arterioscle Thromb Vasc Biol 2002;22:1761–1768.
14.
Skatchkov MP, Sperling D, Hink U, Mulsch A, Harrison DG, Sindermann I, Meinertz T, Munzel T: Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production.Biochem Biophys Res Commun 1999;254:319–324.
15.
Alvarez de Sotomayor M, Perez-Guerrero C, Herrera MD, Jimenez L, Marin R, Marhuenda E, Andriantsitohaina R: Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways. Br J Pharmacol 2005;146:1130–1138.
16.
Takase H, Dohi Y, Kojima M, Sato K: Changes in the endothelial cyclooxygenase pathway in resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1994;23:326–330.
17.
Diederich D, Yang ZH, Buhler FR, Luscher TF: Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 1990;258:H445–H451.
18.
Matrougui K, Maclouf J, Lévy BI, Henrion D: Impaired nitric oxide- and prostaglandin-mediated responses to flow in resistance arteries of hypertensive rats. Hypertension 1997;30:942–947.
19.
Athanassakis I, Dionyssopoulou E, Papanikou S, Athanassios E, Vassiliadis S: Early events of the exogenously provided L-carnitine in murine macrophages, T- and B-lymphocytes: modulation of prostaglandin E1 and E2 production in response to arachidonic acid. J Nutr Biochem 2003;14:350–357.
20.
Izgüt-Uysal VN, Agac A, Derin N: Effect of carnitine on stress-induced lipid peroxidation in rat gastric mucosa. J Gastroenterol 2001;36:231–236.
21.
Vaziri ND, Ni Z, Oveisi F: Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 1998;31:1248–1254.
22.
Ulker S, McMaster D, McKeown PP, Bayraktutan U: Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res 2003;59:488–500.
23.
Crabos M, Coste P, Paccalin M, Tariosse L, Daret D, Besse P, Bonoron-Adele S: Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol 1997;29:55–65.
24.
Chou TC, Yen MH, Li CY, Ding YA: Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998;31:643–648.
25.
Babior BM: NADPH oxidase: an update. Blood 1999;93:1464–1476.
26.
Griedling KK: Novel NAD(P)H oxidases in the cardiovascular system. Heart 2004;90:491–493.
27.
Li H, Witte K, August M, Brausch I, Godtel-Armbrust U, Habermeier A, Closs EI, Oelze M, Munzel T, Forstermann U: Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Col Cardiol 2006;47:2536–2544.
28.
Lodi F, Cogolludo A, Duarte J, Moreno L, Coviello A, Peral de Bruno M, Vera R, Galisteo M, Jimenez R, Tamargo J, Perez-Vizcaino F: Increased NADPH oxidase activity mediates spontaneous aortic tone in genetically hypertensive rats. Eur J Pharmacol 2006;544:97–103.
29.
Lassègue B, Clempus RE: Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003;285:R277–R297.
30.
Chan SH, Tai MH, Li CY, Chan JY: Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. Free Radic Biol Med 2006;40:2028–2039.
31.
Janiszewski M, Souza HP, Liu X, Pedro MA, Zweier JL, Laurindo FRM: Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts. Free Radic Biol Med 2002;32:446–453.
32.
Stroh R, Christopher TA, Lopez BL, Guo YP, Amico-Roxas M, Ma XL: L-Propionyl carnitine, an endogenous ester in fatty acid metabolism, exerts anti-shock and endothelial protective effects in rat splanchnic ischemia-reperfusion injury. Shock 1998;9:216–222.
33.
Irat AM, Aktan F, Ozansoy G: Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotozin-diabetic rat aorta. J Pharm Pharmacol 2003;55:1389–1395.
34.
Calo LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M, Pessina AC: Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006;107:54–60.
35.
Jiang F, Roberts SJ, Datla SR, Dusting GJ: NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006;48:950–957.
36.
Goto K, Rummery NM, Grayson TH, Hill CE: Attenuation of conducted vasodilatation in rat mesenteric arteries during hypertension: role of inwardly rectifying potassium channels. J Physiol 2004;561:215–231.
37.
Kansui Y, Fujii K, Goto K, Abe I, Iida M: Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide-mediated relaxations in arteries of hypertensive rats. Clin Exp Pharmacol Physiol 2004;31:354–359.
38.
Mauriello A, Sangiorgi G, Orlandi A, Schiaroli S, Perfumo S, Spagnoli LG: Effect of long-term treatment with propionyl-L-carnitine on smooth muscle cell polyploidy in spontaneously hypertensive rats. Hypertension 1996;28:177–182.
39.
Digiesi V, Cantini F, Bisi G, Guarino G, Brodbeck B: L-Carnitine adjuvant therapy in essential hypertension. Clin Ter 1994;144:391–395.
40.
Loffredo L, Pignatelli P, Cangemi R: Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. J Vasc Surg 2006;44:525–530.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.